Lee SH, Govindaiah G, Cox CL. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol 103: 1728 -1734, 2010. First published January 27, 2010 doi:10.1152/jn.00540.2009. The thalamic reticular nucleus (TRN) consists of GABA-containing neurons that form reciprocal synaptic connections with thalamic relay nuclei. Excitatory synaptic innervation of TRN neurons arises from glutamatergic afferents from thalamocortical relay neurons and deep layer corticothalamic neurons, and they produce excitation via both N-methyl-D-aspartate (NMDA) and non-NMDA receptors. Quinoxaline derivatives [e.g., 6,7-dinitroquinoxaline-2,3-dione (DNQX), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)] have routinely been used as non-NMDA receptor antagonists over the last two decades. In this study, we examined whether quinoxaline derivatives alter the intrinsic properties of thalamic neurons in light of recent findings indicating that these compounds can alter neuronal excitability in hippocampal and cerebellar neurons via transmembrane AMPA receptor (AMPAR) regulatory proteins (TARPs). Whole cell recordings were obtained from TRN and ventrobasal (VB) thalamic relay neurons in vitro. DNQX and CNQX produced a consistent depolarization in all TRN neurons tested. The depolarization persisted in tetrodotoxin and low Ca 2ϩ /high Mg 2ϩ conditions, suggesting a postsynaptic site of action. In contrast, DNQX and CNQX produced little or no change in VB thalamocortical relay neurons. The nonspecific ionotropic glutamate receptor antagonist, kynurenic acid, and the selective AMPAR antagonist, 4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-y l)-benzenamine hydrochloride, blocked the DNQX-mediated depolarizations. Our results indicate that the DNQX-and CNQX-mediated depolarizations are mediated by AMPAR but not kainate receptors in TRN neurons. The AMPAR-positive allosteric modulator, trichloromethiazide, potentiated the DNQX-mediated depolarization in TRN neurons but did not unmask any excitatory actions of DNQX/CNQX in relay neurons. This selective action may not only reveal a differential TARP distribution among thalamic neurons but also may provide insight into distinct characteristics of AMPA receptors of thalamic neurons that could be exploited by future pharmacological development. Furthermore, these data suggest that quinoxaline derivatives could modulate synaptic transmission and alter neuronal excitability.
I N T R O D U C T I O N
In the mammalian CNS, ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors (AMPARs) mediate fast, glutamatergic excitatory synaptic transmission. The activation of AMPARs gives rise to transient postsynaptic depolarizations that can lead to action potential discharge in the postsynaptic neurons. AMPARs also play many important roles in several forms of synaptic plasticity (e.g., short-term, long-term, homeostatic synaptic plasticity) and contribute to several pathological conditions, including epilepsy and stroke (Malinow and Malenka 2002; Rogawski and Donevan 1999; Song and Huganir 2002; Turrigiano and Nelson 2004; Weiser 2005) . The thalamic reticular nucleus (TRN) consists of GABA-containing neurons that provide synaptic inhibition of neurons in thalamic relay nuclei. The TRN is situated at a unique location on the interface of thalamocortical and corticothalamic pathways and thus provide feedforward and -back inhibition of thalamic relay nuclei (Jones 1975; Sherman and Guillery 1996) . As in other brain areas, AMPARs mediate the vast majority of excitatory synaptic transmission in the TRN.
AMPARs are a heterogeneous group of receptors in the CNS neurons. Four distinct subunits (i.e., GluA1, GluA2, GluA3, GluA4) combine to form homo-or heterotetramers that function differently (Dingledine et al. 1999) . The existence of splice variants for each AMPA receptor subunit (i.e., flip, flop) gives rise to heterogeneity among each subunit. Thus distinct cell types may differ widely in receptor composition leading to differences in AMPAR kinetics and influence of AMPARs modulators. Transmembrane AMPAR-regulatory proteins (TARPs), which are AMPAR auxiliary subunits thought to contribute to the functional diversity among AMPARs, are differentially expressed in the CNS [i.e., ␥-2 (or stargazin), ␥-3, ␥-4, ␥-7, and ␥-8] (Kato et al. 2007; Moss et al. 2003; Nicoll et al. 2006; Sharp et al. 2001; Tomita et al. 2003) . TARPs play critical roles not only in AMPAR surface expression, synaptic targeting, stabilization, and recycling but also in the modulation of deactivation, desensitization, and opening time of AMPARs (Chen et al. 2000; Milstein and Nicoll 2008; Nicoll et al. 2006; Tomita et al. 2003 Tomita et al. , 2005 Ziff 2007 ). In the thalamus, there is a relatively higher density of GluA4 in TRN neurons, which is associated with a larger quantal size of excitatory postsynaptic currents (EPSCs) compared with thalamocortical relay neurons (Golshani et al. 2001) , suggesting the functional and anatomical diversity of AMPARs.
Quinoxaline derivatives [e.g., 6,7-dinitroquinoxaline-2,3-dione (DNQX), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)] have routinely been used over several decades as non-N-methyl-Daspartate (non-NMDA) glutamate receptor antagonists. Limited studies suggest that some quinoxaline derivatives can depolarize CA1 interneurons and cerebellar Golgi cells (Maccaferri and Dingledine 2002; Menuz et al. 2007 ). Recent studies suggest that these agents may serve as partial agonists in the presence of TARPs and concluded that agonist activity of CNQX may be a general property of CNS neurons and AMPA receptors (Menuz et al. 2007) . In these studies, AMPARs in hippocampal and cerebellar neurons consist of GluA2 subunits in combination with GluA1 and GluA3 subunits (Keinanen et al. 1990; Martin et al. 1993; Zhu et al. 2000) , and the TARPs associated with these neurons include ␥2 (predominant subtype in cerebellum), ␥3, ␥4, and ␥8 (predominant subtype in hippocampus) . In contrast, AMPARs in rodent thalamic neurons consist primarily of GluA3 and GluA4 subunits with the notable absence of GluA1 and GluA2 subunits (Golshani et al. 2001; Ibrahim et al. 2000; Jones 2002; Mineff and Weinberg 2000) . The TARPs associated with thalamic neurons include ␥2, ␥3, ␥4, and ␥7; however, their expression patterns within distinct thalamic neuron populations have not been described (Chen et al. 2000; Fukaya et al. 2005; Kato et al. 2007; Klugbauer et al. 2000; Letts et al. 1998; Moss et al. 2003; Tomita et al. 2003) . In the present study, we examined if quinoxaline derivatives alter the membrane properties of thalamic neurons in a similar manner as that recently reported in hippocampal and cerebellar neurons (Menuz et al. 2007 ). Our results indicate that the quinoxaline derivatives, CNQX and DNQX, selectively depolarize TRN neurons but not thalamocortical relay neurons via the direct activation of postsynaptic AMPARs. Thus we speculate that these differential actions of DNQX and CNQX among thalamic neurons may reveal a difference in TARP distribution when AMPARs consist of GluA3 and GluA4 subunits.
M E T H O D S
The present study was performed on brain slices that contain both the thalamic reticular nucleus (TRN) and ventrobasal nucleus (VB) from Sprague-Dawley rats (postnatal age 10 -18 days) in a manner similar to those previously described (Lee et al. 2007 ). All experimental procedures were carried out in accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the University of Illinois Animal Care and Use Committee. Briefly, animals were deeply anesthetized with sodium pentobarbital (50 mg/kg) and decapitated. The brain was quickly removed and placed into cold, oxygenated slicing medium containing (in mM) 2.5 KCl, 10.0 MgCl 2, 0.5 CaCl 2, 1.25 NaH 2 PO 4, 26.0 NaHCO 3, 11.0 glucose, and 234.0 sucrose. Tissue slices (250 -300 m thickness) were cut in the horizontal plane using a vibrating tissue slicer, transferred to a holding chamber, and incubated Ն1 h before recording. Individual slices were then transferred to a recording chamber and continuously superfused with oxygenated physiological saline at 30°C. The physiological solution contained (in mM) 126.0 NaCl, 2.5 KCl, 2.0 MgCl 2 , 2.0 CaCl 2 , 1.25 NaH 2 PO 4 , 26.0 NaHCO 3 , and 10.0 glucose. This solution was gassed with 95% O 2 -5% CO 2 to a final pH of 7.4. Intracellular recordings, using the whole cell configuration were obtained with the visual aid of a modified Nikon microscope equipped with differential interference contrast optics. A low-power objective was used to identify various thalamic nuclei, and a high-power water-immersion objective was used to visualize individual neurons. Recording pipettes were pulled from 1.5-mm OD capillary tubing and had tip resistances of 3-6 M⍀ when filled with the following intracellular solution (in mM): 117 K-gluconate, 13 KCl, 1.0 MgCl 2 , 0.07 CaCl 2 , 0.1 EGTA, 10.0 HEPES, 2.0 Na 2 -ATP, and 0.4 Na-GTP. The pH was adjusted to 7.3 using KOH and osmolarity was adjusted to 290 -300 mosM with distilled H 2 O. Voltage and current recordings were obtained using a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA). Current and voltage protocols were generated using pClamp software (Molecular Devices), and data were digitized and stored on computer. The apparent input resistance of the neuron was calculated from the linear slope of the voltage-current relationship obtained by applying constant current pulses ranging from Ϫ100 to ϩ40 pA (800-ms duration). The brief downward responses in all voltage recordings are membrane responses to brief hyperpolarizing current steps, which were used to assay alterations in input resistance. In some cases (e.g., Figs. 1D and 2A), during the peak of the quinoxaline-mediated depolarization, the membrane potential was returned to baseline levels with DC current injection to nullify voltage-dependent contributions to changes in the responses to the brief current steps. We corrected all voltage measurements for liquid junction potential error by adding Ϫ10 mV.
Concentrated stock solutions of DNQX, CNQX, 2,3-dioxo-6-nitro-
, and trichloromethiazide (TCM) were dissolved in DMSO. (2S,4R)-4-methylglutamic acid (SYM2081) was prepared in distilled water, and kynurenic acid was prepared in physiological saline at final concentration. Stock solutions were diluted in physiological saline to a final concentration just prior to application. DNQX, CNQX, and NBQX were applied by injecting a bolus into the input line of the chamber over 60 s using a motorized syringe pump. Based on the rate of syringe pump and chamber perfusion, the final bath concentration of drugs was estimated to one-eighth of the concentration introduced in the flow line (Cox et al. 1995) . In a subpopulation of neurons, CNQX was bath applied for 5 min. Control injections of physiological saline or vehicle (DMSO) did not alter membrane potential/input resistance during voltage recordings. GYKI52466, SYM2081, kynurenic acid, and TCM were bathapplied for Ն7 min before subsequent application of other agents. All compounds were purchased from either Tocris Cookson (Ellisville, MO) or Sigma (St. Louis, MO).
Data are presented as means Ϯ SD. Most statistical analyses consist of unpaired Student's t-test and, when appropriate, paired Students' t-test for paired samples. The difference between the means was considered significant when P Ͻ 0.05.
R E S U L T S
Whole cell current-and voltage-clamp recordings were obtained from 71 TRN neurons and 25 VB thalamocortical relay neurons. All recorded TRN neurons were obtained from the ventral TRN (Lee et al. 2007 ). The average resting membrane potential of TRN neurons (Ϫ75.4 Ϯ 6.8 mV; n ϭ 71) was significantly different from that of VB relay neurons (Ϫ69.8 Ϯ 3.2 mV; n ϭ 25; P Ͻ 0.01). Despite the difference in resting membrane potentials, the apparent input resistance did not significantly differ between the TRN neurons (216.9 Ϯ 101.5 M⍀; n ϭ 71) and the VB relay neurons (246.3 Ϯ 74.8 M⍀; n ϭ 25; P Ͼ 0.5).
DNQX selectively depolarizes TRN neurons
We initially tested the effects of the quinoxaline derivative DNQX on the membrane potential of TRN and VB neurons. DNQX (20 M) produced a slow-onset, long-duration depolarization in all TRN neurons tested with average amplitude of 3.3 Ϯ 1.1 mV (Fig. 1A, n ϭ 13) . In contrast, DNQX (20 M) did not alter the membrane potential (0.2 Ϯ 0.5 mV, n ϭ 6) or input resistance of VB neurons (Fig. 1A) . Accordingly, in voltage-clamp recordings, DNQX (20 M) evoked an inward current that averaged Ϫ14.3 Ϯ 5.6 pA (Fig. 1B , n ϭ 5, P Ͻ 0.01) but not in VB neurons (1.3 Ϯ 2.3 pA, n ϭ 5, P Ͼ 0.1; Fig. 1B) . At a lower concentration, DNQX (4 M) produced a negligible depolarization (0.3 Ϯ 0.3 mV, n ϭ 5) in TRN neurons, but at higher concentrations, DNQX (100 M) produced a larger depolarization that averaged 3.7 Ϯ 1.6 mV ( Fig. 1C; n ϭ 4) .
We next attempted to determine the site of DNQX-mediated depolarization. In the presence of tetrodotoxin (TTX; 0.5 M), which blocks voltage-dependent Na ϩ channels and negates downstream effects via suprathreshold excitation of presynaptic neurons, DNQX (20 M) produced an average depolariza-tion of 2.5 Ϯ 0.5 mV ( Fig. 1D ; n ϭ 6), This amplitude did not differ significantly from that in control conditions (3.3 Ϯ 1.1 mV, n ϭ 13; P Ͼ 0.05; Fig. 1D ). We next tested if the DNQX response persisted after blocking synaptic transmission using a low Ca 2ϩ (0.2 mM)/high Mg 2ϩ (6.0 mM)-containing extracellular solution. In this condition, DNQX produced a depolarization averaging 3.0 Ϯ 0.5 mV (n ϭ 6; Fig. 1D ) that did not differ significantly from the depolarization produced by DNQX in either control conditions or TTX (P Ͼ 0.5; Fig. 1D ). These data indicate that the DNQX-mediated depolarization is mediated via a postsynaptic mechanism.
We next tested if other quinoxaline derivatives, CNQX and NBQX, would produce similar actions as DNQX. CNQX (20 M) depolarized all TRN neurons tested in a similar manner as DNQX ( Fig. 2A, n ϭ 16) . The CNQX-mediated depolarization averaged 5.0 Ϯ 2.2 mV (n ϭ 16). It is important to note that with longer CNQX application [5 min (n ϭ 9) vs. 1 min (n ϭ 7)], the depolarization persisted throughout CNQX application ( Fig. 2A) . In contrast, NBQX (20 M) did not alter the membrane potential (0.1 Ϯ 0.2 mV, n ϭ 5) or input resistance in the TRN neurons ( Fig. 2A) . Our population data clearly indicate the differential effects of CNQX, DNQX, and NBQX on the membrane potential of TRN neurons (Fig. 2C) . In VB neurons, CNQX (20 M) and NBQX (20 M) produced negligible effects on the membrane potential (Fig. 2B , CNQX: 0.7 Ϯ 0.3 mV, n ϭ 11; NBQX: Ϫ0.02 Ϯ 0.54 mV, n ϭ 5).
Role of AMPA receptors in the quinoxaline-mediated depolarization
Considering the recent finding that quinoxaline derivatives may act as partial agonists (Menuz et al. 2007 ), we next examined if DNQX and CNQX could be acting in this manner on thalamic neurons. In the presence of a broad-spectrum ionotropic glutamate receptor (iGluR) antagonist, kynurenic acid (4 mM), the subsequent DNQX (20 M) application did not alter the resting membrane potential ( Fig. 3Ai ; 0.1 Ϯ 0.3 mV; n ϭ 5). We next tested if the noncompetitive AMPA receptor antagonist, GYKI 52466, could attenuate the DNQXmediated effects on TRN neurons. In the presence of GYKI 52466 (50 M), DNQX did not alter the membrane potential of the TRN neurons ( Fig. 3Aii ; 0.1 Ϯ 0.2 mV; n ϭ 5), suggesting the direct activation of postsynaptic AMPA receptors of TRN neurons by DNQX. It is important to note that GYKI 52466 alone did not alter the membrane potential of the TRN neurons ( Fig. 3Aii; Ϫ0 .1 Ϯ 0.1 mV, n ϭ 5; P Ͼ 0.1). In contrast to GYKI 52466 and kynurenic acid, SYM 2081, a selective kainate receptor antagonist, did not alter the DNQX-mediated depolarizations. In SYM 2081 (40 M), DNQX (20 M) depolarized all TRN neurons tested to a magnitude that did not differ from that in the absence of SYM 2081 ( Fig. 3Aiii ; 2.9 Ϯ 1.1 mV, n ϭ 4; P Ͼ 0.5). As illustrated in Fig. 3B , the DNQX-mediated membrane depolarization is selectively blocked by AMPAR antagonists. In VB neurons, GYKI 52466 (50 M) blocked the small CNQX-mediated depolarization of membrane potential (CNQX: 0.79 Ϯ 0.33 mV, CNQXϩGYKI 52466: 0.14 Ϯ 0.20 mV, n ϭ 5, P Ͻ 0.05).
Recent studies indicate that an AMPAR-positive allosteric modulator, trichloromethiazide (TCM) can potentiate or unmask excitatory actions of CNQX in cerebellar Golgi cells and CA1 pyramidal cells (Menuz et al. 2007 ). We tested whether TCM could enhance the DNQX-mediated responses in TRN neurons, and possibly unmask an excitation of VB neurons. In the presence of TCM (500 M), DNQX (20 M) produced a robust membrane depolarization with peak amplitude that averaged 12.5 Ϯ 3.1 mV (Fig. 4Ai , n ϭ 6) in TRN neurons. This depolarization was significantly larger than that produced in the absence of TCM (Fig. 4B , P Ͻ 0.01). In VB neurons, similar to what we observed in control conditions, DNQX (20 M) did not alter the membrane potential in the presence of TCM (500 M; Fig. 4Aii ). This lack of effect of TCM unmasking a DNQX depolarization was consistent in all neurons tested ( Fig. 4B ; 0.2 Ϯ 0.5 mV, n ϭ 6, P Ͼ 0.1). Similarly, in VB neurons, in the presence of TCM, subsequent application of CNQX did not unmask a larger depolarization by CNQX. The small depolarization produced by CNQX in control conditions did not significantly differ from that produced in the presence of TCM (n ϭ 5; P Ͼ 0.05).
D I S C U S S I O N
In the present study, we found that the quinoxaline derivatives, DNQX and CNQX, but not NBQX, depolarized TRN neurons. In contrast, these compounds produced negligible or no alterations in VB thalamocortical neurons. In TRN neurons, AMPAR antagonists blocked the DNQX-and CNQX-medi- ated membrane depolarizations, and the depolarizations were significantly enhanced by the positive allosteric AMPAR modulator trichloromethiazide. In thalamocortical relay neurons, trichloromethiazide neither unmasked nor potentiated the excitatory actions of DNQX/CNQX, suggesting a differential distribution of AMPAR subunits between these two nuclei. Our results indicate that the DNQX and CNQX may act as partial agonists on AMPARs in TRN neurons leading to the membrane depolarization. Recent studies suggest that the presence of TARPs can determine whether the quinoxaline derivatives act as an agonist or antagonist (Menuz et al. 2007 ). Thus the differential actions of DNQX/CNQX among thalamic neurons may reveal a difference in the TARP distribution across thalamic regions.
Quinoxaline derivatives selectively depolarize TRN neurons
In the hippocampus and cerebellum, CNQX has been found to increase inhibitory activity in excitatory neurons by an increase in excitatory response in GABAergic interneurons (Maccaferri and Dingledine 2002; McBain et al. 1992; Menuz et al. 2007 ). Our findings are consistent in that we find CNQX and DNQX can produce membrane depolarization of GABAcontaining TRN neurons; this would in turn alter inhibitory activity onto thalamic relay neurons. Furthermore the quinoxalinedione-induced depolarization is blocked by AMPAR antagonists, leading to the conclusion that DNQX and CNQX are acting as partial agonists on AMPARs. We also found that the AMPAR allosteric modulator trichloromethiazide potentiated the excitatory action of DNQX on TRN neurons. In CA1 pyramidal neurons, the allosteric modulator unmasked an excitatory action of CNQX that was not present in the absence of the modulator (Menuz et al. 2007 ); however, our results clearly indicate that the excitatory actions of quinoxaline derivatives cannot be generalized to all excitatory neurons because in thalamocortical relay neurons, the allosteric modulator did not unmask an excitatory response to the quinoxaline derivatives.
The excitatory actions of these quinoxalinedione agents in the CNS are of considerable interest because the agonist-like actions of quinoxalinedione appear due to the presence of TARPs (Menuz et al. 2007 ). In HEK293 cells, quinoxaline derivatives only act as partial agonists when specific TARP subtypes (i.e., ␥2, ␥3, ␥4, ␥8) were co-expressed with GluA1 but not when GluA1 was solely expressed in HEK293 cells alone. Considering nearly all central nervous neurons express one or more TARPs and TARPs are essential for the partial agonist actions of these agents, the excitatory actions of these agents could be ubiquitous. This conclusion was further supported by data in which excitatory actions of CNQX were unmasked by the positive AMPAR modulator. However, our findings indicate such actions are not ubiquitous and further raise the possibility that VB neurons could express TARP-less AMPARs. Considering TARPs are essential for rendering the partial agonist action of CNQX (Menuz et al. 2007) , the differential actions of CNQX on TRN and VB relay neurons is consistent with the notion that VB neurons could express TARP-less AMPA receptors (Schwenk et al. 2009 ). However, the differential effect of the AMPAR modulator could reflect a difference in AMPA receptor splicing isoforms, flip and flop, between TRN and VB neurons. The stronger effect of the positive AMPAR modulator on TRN neurons could reflect that TRN neurons express more flip isoforms, which would express more AMPA receptor/TARP complex compared with the VB neurons, and thereby produce greater quinoxaline sensitivity (Menuz et al. 2007; Partin et al. 1994) .
Alternatively, the differential effect of DNQX/CNQX on TRN and VB neurons could indicate a differential distribution of AMPAR and/or TARP subunits. Several TARPs (i.e., ␥2, ␥3, ␥4, and ␥7) are expressed throughout the thalamus, but their cellular expression patterns have not been described (Chen et al. 2000; Fukaya et al. 2005; Kato et al. 2007; Klugbauer et al. 2000; Letts et al. 1998; Moss et al. 2003; Tomita et al. 2003) . This distribution suggests that relay neurons may express multiple types of TARPs, but despite that we did not observe excitatory actions of DNQX alone or in the presence of a positive AMPA receptor modulator on relay neurons. Miniature EPSC amplitude and frequency appear selectively decreased in TRN neurons but not in relay neurons from functional ␥2-lacking mice (Stargazer mice) (Menuz and Nicoll 2008) . Considering TARPs are essential for maintaining neuronal AMPAR expression, relay neurons must express other TARPs to maintain the normal function of AMPARs in addition to ␥2. Furthermore, DNQX/CNQX may not act as partial agonists when other AMPAR subtypes (i.e., GluA3, GluA4) that are highly localized in the thalamus (Jones 2002; Mineff and Weinberg 2000) are coexpressed with TARP subtypes, whereas DNQX/CNQX act as partial agonist when AMPAR subtypes (i.e., GluA1, GluA2), which are highly localized in hippocampal pyramidal cells (Keinanen et al. 1990; Zhu et al. 2000) but appear absent in rodent thalamus (Liu 1997) , are coexpressed with TARP subtypes. Albeit, we cannot completely rule out that low levels of GluA1 and/or GluA2 could be present in the thalamic neurons thereby contributing to the quinoxaline effect. Menuz et al. (2007) reported that all TARPs when coexpressed with GluA1 (not other subtypes) showed the partial agonist effect, but there is no evidence concerning GluA3 and GluA4, which are important AMPARs subunits in rodent thalamic neurons. Thus whether all TARPs when coexpressed with other subtypes (i.e., GluA2, GluA3, GluA4) show the effect of partial agonism is still unknown.
Implications for thalamocortical function
One of the important issues is that the differential actions of CNQX/DNQX on neuronal excitability of TRN and VB neurons may shed light on fundamental processes in thalamic function. Considering the potential role of TARPs and positive modulators in modifying AMPAR-mediated actions could these differential actions in TRN and relay neurons allow for selective targeting of pharmacological intervention? For example, intrathalamic rhythmic activity observed during certain pathophysiological conditions such as absence epilepsy requires the reciprocal synaptic interaction between TRN and thalamocortical relay neurons. The modulation of TARP activity could serve to disrupt the rhythmic activity by selectively altering the membrane potential of TRN neurons and thereby change the output mode of these cells without directly altering thalamic relay neurons. The dampening of rhythmic activity associated with absence epilepsy is presently achieved using pharmacological agents (e.g., ethosuximide) that dampen activity of all thalamic neurons. Although the selective excitation of TRN neurons by CNQX/DNQX serves as a secondary effect of these antagonists, such selective action may provide insight into distinct characteristics of thalamic neurons that could be exploited by future pharmacological developments. Stargazer mice have the mutated protein, stargazin (i.e., ␥2 TARP), which leads to ataxia and seizures that resemble absence epilepsy (Letts et al. 1998) . In this animal model, there is a selective loss of functional AMPARs in TRN neurons, but not in thalamic relay neurons, indicative of a clear difference in TARPs between TRN and relay neurons. Considering the decrease in functional AMPARs in TRN neurons by stargazin, is associated with absence-like epileptiform activity, selective enhancement of currents mediated by stargazin-associated AMPA receptors may attenuate absence-like epileptiform activity without altering "normal" functioning of thalamic relay neurons. 
